{
    "eid": "2-s2.0-85147677571",
    "title": "Development of Clinical Prediction Score for Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients",
    "cover-date": "2023-02-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Leadership and Management",
            "@code": "2911",
            "@abbrev": "NURS"
        },
        {
            "@_fa": "true",
            "$": "Health Policy",
            "@code": "2719",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Health Informatics",
            "@code": "2718",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Health Information Management",
            "@code": "3605",
            "@abbrev": "HEAL"
        }
    ],
    "keywords": [
        "advanced lung cancer",
        "chemotherapy",
        "clinical prediction rule",
        "decision making",
        "limited resources"
    ],
    "authors": [
        "Chawalit Chayangsu",
        "Jiraporn Khorana",
        "Chaiyut Charoentum",
        "Virote Sriuranpong",
        "Jayanton Patumanond",
        "Apichat Tantraworasin"
    ],
    "citedby-count": 0,
    "ref-count": 26,
    "ref-list": [
        "Cancer Statistics, 2022",
        "Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology",
        "Emerging Therapies for Non-Small Cell Lung Cancer",
        "Value-Based Care in Lung Cancer",
        "Epidermal Growth Factor Receptor Mutation Testing in Thailand: A Cost-Utility Analysis",
        "Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients with Curable Cancers",
        "Influence of Body Mass Index on the Therapeutic Efficacy of Gemcitabine plus Cisplatin and Overall Survival in Lung Squamous Cell Carcinoma",
        "Individual-Level Data on the Relationships of Progression-Free Survival and Post-Progression Survival with Overall Survival in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Patients Who Received Second-Line Chemotherapy",
        "Early Response to Platinum-Based First-Line Chemotherapy in Non-Small Cell Lung Cancer May Predict Survival",
        "Age Is a Prognostic Factor Affecting Survival in Lung Cancer Patients",
        "Evaluating Prognostic Factors for Sex Differences in Lung Cancer Survival: Findings from a Large Australian Cohort",
        "Smoking History as a Predictive Factor of Treatment Response in Advanced Non\u2013Small-Cell Lung Cancer: A Systematic Review",
        "Prognosis in Advanced Lung Cancer\u2014A Prospective Study Examining Key Clinicopathological Factors",
        "Definition and Classification of Cancer Cachexia: An International Consensus",
        "The Predictive Value of Pre-Treatment Inflammatory Markers in Advanced Non-Small-Cell Lung Cancer",
        "Carcinoembryonic Antigen (CEA) as Tumor Marker in Lung Cancer",
        "The Emerging Treatment Landscape of Targeted Therapy in Non-Small-Cell Lung Cancer",
        "Targeted Therapy in Advanced Non-Small Cell Lung Cancer: Current Advances and Future Trends",
        "DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy",
        "ERCC1-Specific Immunostaining in Non-Small-Cell Lung Cancer",
        "Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients",
        "Predictors of Chemotherapy Efficacy in Non-Small-Cell Lung Cancer: A Challenging Landscape",
        "Texture Analysis of Advanced Non-Small Cell Lung Cancer (NSCLC) on Contrast-Enhanced Computed Tomography: Prediction of the Response to the First-Line Chemotherapy",
        "Prediction of Early Response to Chemotherapy in Lung Cancer by Using Diffusion-Weighted MR Imaging",
        "Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-Based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups",
        "P2.03a-033 Prediction of Response to First Line Treatment for Metastatic Non-Small Cell Lung Cancer"
    ],
    "affiliation": [
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60032250",
            "affilname": "Faculty of Medicine, Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032250",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nakhon Ratchasima",
            "@id": "60026326",
            "affilname": "Suranaree University of Technology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026326",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60000881",
            "affilname": "Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}